Solar Pharmaceutical Industries Ltd.’s revenue declined within the fourth quarter of fiscal 12 months 2024-25, thereby lacking the estimates shared by analysts.
India’s largest drugmaker’s consolidated web revenue fell 19% year-on-year to Rs 2,154 crore within the March quarter, based on an change submitting on Thursday. That compares with the Rs 2,794-crore consensus estimate of analysts tracked by Bloomberg.
Solar Pharma This fall FY25 Highlights (YoY)
-
Income up 8% at Rs 12,959 crore versus Rs 11,983 crore (Bloomberg estimate: Rs 13,254 crore).
-
Ebitda up 22.4% at Rs 3,716 crore versus Rs 3,035 crore (Bloomberg estimate: Rs 3,651 crore).
-
Margin at 28.7% versus 25.3% (Bloomberg estimate: 27.5%).
-
Web revenue down 19% to Rs 2,154 crore versus Rs 2,659 crore (Bloomberg estimate: Rs 2,794 crore).
The corporate has additionally declared a dividend of Rs 5.5 per share.
(It is a creating story)
. Learn extra on Earnings by Newsstate24 Revenue.
